While the last-to-expire patent was a device patent in just one-fifth of cases, more than half of all patents listed with the FDA covering GLP-1 receptor agonists were on the delivery devices rather than active ingredients, methods of use, or formulations, which can make it difficult for generic firms to obtain FDA approval for their products
Ferroptosis: An emerging therapeutic opportunity for cancer
The evaluation of GPx activity, glutathione reductase (GR), SOD, total serum antioxidant status (TAS), MDA and 8-OHdG in ALS patients, found a significant decrease in TAS levels and an increase of 8-OHdG and MDA levels, together with significantly higher oxidized/reduced glutathione (GSSG/GSH) ratio and IL-6 and IL-8 (Blasco et al., 2017)
Who Might Benefit from Microdosing
2025 Jan-
10.2478/acph-2022-0040 Acta Pharm